ArticleDiagnostics (Basel, Switzerland)2026
Post-Treatment NLR and SII Associations with Response and Progression-Free Survival After Neoadjuvant Disitamab Vedotin Plus PD-1 Blockade in Muscle-Invasive Bladder Cancer: A Real-World Cohort Study.
Yongsheng Huang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.